Feb 24,2023

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

Nemaura Medical, Inc. today releases its financial results for the quarter ending December 31, 2022 and provides a business update. Net loss for the quarter was approximately $1.7million. Cash and cash equivalents at December 31, 2022 were approximately $7.3 million. “We continue to build momentum with our UK programs, while initiating our foothold in the U.S. The recent purchase order from HealthFleet marks the beginning of our commercialization efforts in the U.S., integrating our proBEAT technology into HealthFleet’s RestoreHealth program to potentially improve diabetes management and weight loss.'' commented Nemaura CEO Dr. Faz Chowdhury.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 24,2023 TOP STORY

MiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study

Medtronic today announced one-year data from the ADAPT study (n=82), the first multi-national randomized controlled study comparing the performance of the MiniMed™ 780G advanced hybrid closed loop system1 (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM). The study was done in adults (18 years of age and older) not meeting glycemic targets. The initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% absolute increase in Time in Range (TIR) and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. These latest results were presented today at the 2023 Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Berlin.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Abbott Announces Collaborations, Reinforces its Commitment Towards Access to Holistic Diabetes Care

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher a new era of holistic diabetes management care. Gautam Chopra, Co-founder & CEO, BeatO commented, “Leveraging Abbott’s FreeStyle Libre with BeatO’s app ecosystem will give our users precise data, along with actionable insights to effectively manage and control blood glucose levels. We are continuously striving to make diabetes management more effective and convenient for our members and this program is a step in the same direction.”

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

One Drop Gives Back to Diabetes Community with Donation to Insulin for Life USA

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, has donated diabetes management supplies valued at $38,786 to 501(c)3 charitable organization, Insulin for Life USA (IFL USA). The Florida-based non-profit received 1,000 50ct boxes of test strips, 200 glucose meter kits, and 200 carry cases from One Drop, which they intend to distribute free of charge to children and adults with diabetes in need.

View Analyst & Ambassador Comments
Go to original news
Aug 25,2022

One Drop Improves Workplace Productivity for Older Adults with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced analyses from a randomized control trial (RCT) on the impact of its award-winning digital health platform on workplace productivity (presenteeism) among people with type 2 diabetes published in the Journal of Occupational Environmental Medicine (JOEM). Employees using One Drop experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 23,2017

Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $1.25 per share. The gross proceeds to Tandem from this offering are expected to be $22.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem. 

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Jan 23,2020

Virgin Pulse acquires diabetes startup Blue Mesa Health

Employer health tech company Virgin Pulse has its eyes set on the diabetes space with the recent acquisition of digital therapeutic Blue Mesa Health, best known for its diabetes prevention program Transform. The financial details of the deal were not released. Following the announcement, Blue Mesa Health’s technology will now be rolled into a new offering called Virgin Pulse Transform. The service will be integrated in Virgin Pulse’s existing platform and come in five languages including English, Spanish, Chinese, Portuguese and Arabic.

COLLABORATION MERGERS & ACQUISITION

#product & service

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 13,2020

One Drop Acquires Sano

One Drop, a leader in digital care solutions for people living with diabetes and other chronic conditions, today announced it has acquired all of the assets and intellectual property of Sano Intelligence, Inc., an innovator in health sensing technology. The deal was structured as an asset purchase, and several Sano team members will be joining One Drop. The almost decade of work put into developing the Sano continuous glucose sensing platform will live on in a comprehensive multi-sensorial solution from One Drop.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 16,2020

Amalgam Rx Announces Addition of Digital All-Stars to Leadership Team

Amalgam Rx, Inc., a leading Digital Therapeutics and Patient Support company, is announcing the hiring of a new president, Chris Bergstrom, former partner and head of digital therapeutics at Boston Consulting Group, and the appointment of Sonny Vu, serial entrepreneur, chief executive officer of AREVO, and former founder of Misfit to its Board of Directors. Vu will be joining Ryan Sysko and Jeff Courtney on the Board of Directors.

View Analyst & Ambassador Comments
Go to original news
Jun 08,2017

New OneTouch Reveal Mobile App Empowers People with Diabetes

The new OneTouch Reveal mobile app, introduced today at the 77th Scientific Sessions of the American Diabetes Association, includes several user-inspired features—including blood sugar and activity timelines transformed into quick visual snapshots—allowing people with diabetes to see their results, connect their actions with trends, and get back to their daily life. The OneTouch Reveal® mobile app seamlessly syncs with the OneTouch Verio Flex™ blood glucose monitoring (BGM) system with built-in Bluetooth® Smart Technology.

PRODUCT

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES